Five patients achieved a confirmed tumor response including 1 complete response and 4 partial responses (PR), among whom 4 patients had PIK3CA mutations in the dose-expansion stage and one colorectal cancer patient had unknown PIK3CA mutation status in the dose escalation stage. This evidence concerns the gene PIK3CA and neoplasm.